Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) have received a consensus recommendation of “Buy” from the thirteen research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $29.44.

Several equities research analysts recently issued reports on ABEO shares. Zacks Investment Research cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, September 13th. Maxim Group restated a “buy” rating and set a $35.00 price objective on shares of Abeona Therapeutics in a research report on Friday, August 10th. ValuEngine upgraded shares of Abeona Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 2nd. Finally, BidaskClub upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd.

Institutional investors and hedge funds have recently made changes to their positions in the business. Knott David M acquired a new stake in shares of Abeona Therapeutics during the first quarter valued at about $101,000. Fortaleza Asset Management Inc. acquired a new stake in shares of Abeona Therapeutics during the second quarter valued at about $104,000. Sabby Management LLC acquired a new stake in shares of Abeona Therapeutics during the first quarter valued at about $187,000. Trexquant Investment LP acquired a new stake in shares of Abeona Therapeutics during the first quarter valued at about $260,000. Finally, MetLife Investment Advisors LLC increased its position in shares of Abeona Therapeutics by 57.8% during the second quarter. MetLife Investment Advisors LLC now owns 19,333 shares of the biopharmaceutical company’s stock valued at $309,000 after acquiring an additional 7,085 shares during the last quarter. Institutional investors and hedge funds own 76.24% of the company’s stock.

Shares of NASDAQ:ABEO traded down $1.38 during midday trading on Friday, hitting $12.63. The company’s stock had a trading volume of 3,218,030 shares, compared to its average volume of 426,277. The company has a market cap of $605.28 million, a P/E ratio of -19.13 and a beta of 1.22. Abeona Therapeutics has a 12-month low of $10.50 and a 12-month high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.06). Abeona Therapeutics had a negative return on equity of 23.02% and a negative net margin of 881.74%. The business had revenue of $0.82 million during the quarter, compared to analysts’ expectations of $1.81 million. analysts expect that Abeona Therapeutics will post -0.79 earnings per share for the current year.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Story: How to Track your Portfolio in Google Finance

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.